Acceleron Pharma (XLRN) Misses Q3 EPS by 1c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.65), $0.01 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.82 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c